Treatment for urinary tract infections in kidney transplant patients
Treatment of Chronic Relapsing Urinary Tract Infection With Bacteriophages in Renal Transplant Patients
This study tests if using special viruses called phages can help kidney transplant patients with tough urinary tract infections caused by resistant bacteria.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | Shahid Beheshti University of Medical Sciences Academic / other |
| Locations | 1 site (Tehran) |
| Trial ID | NCT05967130 on ClinicalTrials.gov |
What this trial studies
This clinical trial focuses on treating urinary tract infections (UTIs) caused by resistant bacteria in kidney transplant recipients using specific phages tailored to each patient's urine culture. The study aims to address the high recurrence rates of UTIs associated with extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriums, which are common in this patient population. Participants will be monitored for their response to the phage therapy through follow-up urine cultures, ensuring a personalized approach to treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are stable kidney transplant recipients experiencing resistant urinary tract infections.
Not a fit: Patients who are currently experiencing rejection periods or are considered frail may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the incidence and recurrence of resistant UTIs in kidney transplant patients.
How similar studies have performed: While phage therapy is a novel approach, there is growing interest and preliminary success in using phages to treat antibiotic-resistant infections, suggesting potential for this method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Stable Kidney Transplant Recipients * Stable Immunosupression Dose * Stable Renal Function * Resistant Urinary Infection with Positive UC Exclusion Criteria: * Rejection periods * Frail Patients
Where this trial is running
Tehran
- Nooshin Dalili — Tehran, Iran, Islamic Republic of (Recruiting)
Study contacts
- Principal investigator: Dalili — Sbmu
- Study coordinator: Dalili
- Email: dr.nooshindalili@gmail.com
- Phone: 00989122404331
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.